Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Pacific Biosciences of California (NAS:PACB) Gross Profit Explanation
Warren Buffett believes that firms with excellent long term economics tend to have consistently higher margins.
Durable competitive advantage creates a high Gross Margin % because of the freedom to price in excess of cost. Companies can be categorized by their Gross Margin %
1. Greater than 40% = Durable competitive advantage
2. Less than 40% = Competition eroding margins
3. Less than 20% = no sustainable competitive advantage
Consistency of Gross Margin is key
Pacific Biosciences of California had a gross margin of 32.40% for the quarter that ended in Jun. 2026 => Competition eroding margins
Pacific Biosciences of California Gross Profit Related Terms
Pacific Biosciences of California Gross Profit Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Pacific Biosciences of California Gross Profit Chart
For the Medical Devices subindustry, Pacific Biosciences of California's Gross Profit, along with its competitors' market caps and Gross Profit data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Pacific Biosciences of California Gross Profit vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Pacific Biosciences of California's Gross Profit distribution charts can be found below:
* The bar in red indicates where Pacific Biosciences of California's Gross Profit falls into.
Gross Profit for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $57.9 Mil.
Gross Profit is the numerator in the calculation of Gross Margin.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
A positive Gross Profit is only the first step for a company to make a net profit. The gross profit needs to be big enough to also cover related labor, equipment, rental, marketing/advertising, research and development and a lot of other costs in selling the products.
Pacific Biosciences of California (PACB) has a Gross Profit of $57.9 Mil as of Jun. 2026. Gross Profit equals net sales less total cost of goods sold. View historical data on Pacific Biosciences of California and its competitors.
Is Pacific Biosciences of California's Gross Profit too high?
Pacific Biosciences of California's current Gross Profit is $57.9 Mil. Overall, Pacific Biosciences of California has a GF Score™ of 58/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Pacific Biosciences of California's Gross Profit compare to DCTH and CLPT?
Pacific Biosciences of California's Gross Profit of $57.9 Mil can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Gross Profit for a Medical Devices & Instruments company?
A good Gross Profit depends on the Medical Devices & Instruments industry context. However, Gross Profit should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Gross Profit mean?
A high Gross Profit can signal that a stock is expensive relative to its fundamentals. Gross Profit equals net sales less total cost of goods sold. View historical data on Pacific Biosciences of California and its competitors. Pacific Biosciences of California's current Gross Profit is $57.9 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Pacific Biosciences of California stock overvalued right now?
Based on GuruFocus' analysis, Pacific Biosciences of California (PACB) is currently considered Modestly Undervalued. The stock's GF Value™ is $1.48, compared to a current price of $1.16 — trading 22% below its estimated fair value. The current Gross Profit is $57.9 Mil. Pacific Biosciences of California's overall GF Score™ is 58/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Gross Profit calculated?
Gross Profit is calculated from a company's financial statements. For Pacific Biosciences of California (PACB), the current Gross Profit is $57.9 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Pacific Biosciences of California (PACB) Overvalued in 2026?
Based on GuruFocus' analysis, Pacific Biosciences of California stock appears to be undervalued.
The current stock price of $1.16 is trading 22% below its estimated GF Value™ of $1.48.
GuruFocus considers Pacific Biosciences of California to be Modestly Undervalued.
Key valuation signals for PACB:
Gross Profit: $57.9 Mil
GF Value™: $1.48 vs. price of $1.16 (22% below fair value)
No single metric tells the full story. See the PACB stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Pacific Biosciences of California Inc is a biotechnology company focused on designing, developing, and manufacturing sequencing solutions that enable scientists and clinical researchers to improve their understanding of the genome and ultimately, resolve genetically complex problems. It operates in, one reportable segment: the development, manufacturing, and marketing of an integrated platform for genetic analysis. The majority of the company's revenue is derived from Americas, followed by Europe Middle East, and Africa and Asia-Pacific.
58GF Score
Get the complete analysis for PACB
Gross Profit is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
PACB has been successfully added to your 
